Nifty
:
24008.00
Sensex
:
79454.47
-265.80 (-1.09%)
-880.34 (-1.10%)
Nifty
Sensex
:
:
24008.00
79454.47
-265.80 (-1.09%)
-880.34 (-1.10%)

Zydus Lifesciences Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 532321 | NSE: ZYDUSLIFE

NSE BSE
1008.20
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  984.00
  •  1026.55
  •  976.00
  •  977.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  5775455
  •  58253.45
  •  1324.30
  •  795.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 88,337.28
  • 19.47
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 86,893.68
  • 0.34%
  • 3.87

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.99%
  • 0.56%
  • 5.41%
  • FII
  • DII
  • Others
  • 7.31%
  • 10.79%
  • 0.94%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.49
  • 6.52
  • 8.96

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.69
  • 13.77
  • 10.79

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.47
  • 26.50
  • 19.20

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.67
  • 24.79
  • 23.45

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.90
  • 3.70
  • 3.71

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.40
  • 15.25
  • 14.77

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
38.14
44.23
45.97
43.5
P/E Ratio
25.08
21.5
20.69
21.86
Revenue
19022
22815
24413
25228
EBITDA
5303
6632
6774
6383
Net Income
3860
4473
4641
4380
ROA
14
14.3
12.8
10.8
P/B Ratio
4.83
4.04
3.44
3.06
ROE
20.67
20.03
17.64
14.24
FCFF
2377.1
2955.97
3836.14
3743.37
FCFF Yield
2.44
3.03
3.93
3.83

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
5,269.10
4,505.20
16.96%
5,237.00
4,368.80
19.87%
6,207.50
5,139.60
20.78%
5,533.80
5,010.60
10.44%
Expenses
3,881.50
3,423.40
13.38%
3,821.00
3,304.90
15.62%
4,123.50
3,634.30
13.46%
3,908.60
3,755.00
4.09%
EBITDA
1,387.60
1,081.80
28.27%
1,416.00
1,063.90
33.10%
2,084.00
1,505.30
38.44%
1,625.20
1,255.60
29.44%
EBIDTM
26.33%
24.01%
27.04%
24.35%
33.57%
29.29%
29.37%
25.06%
Other Income
57.50
58.30
-1.37%
113.60
136.20
-16.59%
63.20
36.00
75.56%
161.70
37.80
327.78%
Interest
32.00
19.80
61.62%
25.10
8.70
188.51%
32.20
18.10
77.90%
34.60
27.70
24.91%
Depreciation
229.00
194.80
17.56%
233.60
184.20
26.82%
215.30
179.80
19.74%
205.30
178.60
14.95%
PBT
1,184.10
925.50
27.94%
1,270.90
1,007.20
26.18%
1,899.70
1,329.20
42.92%
1,547.00
485.80
218.44%
Tax
179.50
213.80
-16.04%
373.10
226.40
64.80%
436.10
216.10
101.80%
321.20
137.20
134.11%
PAT
1,004.60
711.70
41.15%
897.80
780.80
14.98%
1,463.60
1,113.10
31.49%
1,225.80
348.60
251.64%
PATM
19.07%
15.80%
17.14%
17.87%
23.58%
21.66%
22.15%
6.96%
EPS
10.17
7.80
30.38%
9.06
7.91
14.54%
14.11
10.74
31.38%
11.75
2.93
301.02%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
22,247.40
19,547.40
17,237.40
15,109.90
14,403.50
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
Net Sales Growth
16.94%
13.40%
14.08%
4.90%
1.06%
8.26%
10.13%
27.49%
-0.53%
8.96%
 
Cost Of Goods Sold
6,252.40
5,260.10
5,335.70
4,757.00
4,094.20
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
Gross Profit
15,995.00
14,287.30
11,901.70
10,352.90
10,309.30
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
GP Margin
71.90%
73.09%
69.05%
68.52%
71.57%
70.23%
68.54%
69.41%
67.31%
71.64%
67.47%
Total Expenditure
15,734.60
14,248.40
13,665.50
11,935.20
11,018.20
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
6,897.40
Power & Fuel Cost
-
366.30
343.50
299.30
231.60
252.90
231.60
211.40
174.50
155.40
145.40
% Of Sales
-
1.87%
1.99%
1.98%
1.61%
1.77%
1.76%
1.77%
1.86%
1.65%
1.68%
Employee Cost
-
2,789.00
2,456.40
2,177.70
2,069.50
2,169.80
1,903.20
1,644.70
1,485.20
1,119.00
1,096.50
% Of Sales
-
14.27%
14.25%
14.41%
14.37%
15.22%
14.46%
13.76%
15.84%
11.87%
12.67%
Manufacturing Exp.
-
2,758.10
2,639.80
2,272.30
2,271.40
2,230.00
1,923.20
1,680.40
955.30
1,397.60
1,136.90
% Of Sales
-
14.11%
15.31%
15.04%
15.77%
15.65%
14.61%
14.06%
10.19%
14.83%
13.14%
General & Admin Exp.
-
625.00
620.30
506.70
444.00
582.60
583.40
398.70
466.00
356.40
326.80
% Of Sales
-
3.20%
3.60%
3.35%
3.08%
4.09%
4.43%
3.34%
4.97%
3.78%
3.78%
Selling & Distn. Exp.
-
1,800.10
1,674.60
1,373.30
1,358.60
1,468.40
1,033.30
1,129.40
826.40
979.60
1,047.20
% Of Sales
-
9.21%
9.71%
9.09%
9.43%
10.30%
7.85%
9.45%
8.81%
10.39%
12.10%
Miscellaneous Exp.
-
649.80
595.20
548.90
548.90
525.90
371.20
404.40
502.60
416.10
1,047.20
% Of Sales
-
3.32%
3.45%
3.63%
3.81%
3.69%
2.82%
3.38%
5.36%
4.41%
3.82%
EBITDA
6,512.80
5,299.00
3,571.90
3,174.70
3,385.30
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
1,753.90
EBITDA Margin
29.27%
27.11%
20.72%
21.01%
23.50%
19.51%
22.62%
23.66%
20.28%
24.71%
20.27%
Other Income
396.00
369.40
474.60
390.70
47.40
117.10
208.50
133.00
147.10
116.60
57.20
Interest
123.90
81.20
129.90
127.00
158.80
341.80
195.80
110.80
63.10
52.80
67.90
Depreciation
883.20
764.10
722.70
713.00
669.60
696.50
598.60
538.80
373.30
292.10
287.30
PBT
5,901.70
4,823.10
3,193.90
2,725.40
2,604.30
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
1,455.90
Tax
1,309.90
977.50
587.80
511.70
193.60
319.80
530.30
564.40
128.90
177.40
259.40
Tax Rate
22.20%
20.33%
22.70%
18.03%
8.07%
21.39%
22.26%
24.41%
8.00%
8.45%
17.95%
PAT
4,591.80
3,718.10
1,870.30
2,195.40
2,154.20
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
PAT before Minority Interest
4,453.70
3,831.40
2,001.90
2,326.40
2,205.60
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
Minority Interest
-138.10
-113.30
-131.60
-131.00
-51.40
-27.80
-49.90
-34.60
-29.10
-30.40
-37.60
PAT Margin
20.64%
19.02%
10.85%
14.53%
14.96%
8.05%
13.69%
14.33%
15.51%
20.06%
13.28%
PAT Growth
55.43%
98.80%
-14.81%
1.91%
87.68%
-36.30%
5.19%
17.82%
-23.11%
64.64%
 
EPS
45.64
36.95
18.59
21.82
21.41
11.41
17.91
17.02
14.45
18.79
11.41

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
19,829.50
17,515.80
16,999.60
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
Share Capital
100.60
101.20
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
19,728.90
17,414.60
16,897.20
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
Non-Current Liabilities
193.10
-725.00
-193.60
19.40
2,853.90
3,491.10
2,122.20
1,903.30
736.10
1,341.50
Secured Loans
0.00
0.00
0.00
0.00
1,953.60
2,332.80
200.60
319.60
393.80
664.00
Unsecured Loans
0.00
0.00
362.10
609.50
1,261.00
1,616.90
2,354.50
2,148.80
502.60
486.40
Long Term Provisions
309.70
271.80
325.00
309.50
235.20
184.10
155.90
151.20
120.70
90.40
Current Liabilities
5,339.70
5,526.70
7,826.80
7,861.30
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
Trade Payables
2,126.70
2,125.00
2,137.80
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
Other Current Liabilities
1,677.60
1,798.50
1,967.50
2,166.20
2,126.30
2,033.60
1,484.90
1,212.10
860.70
628.20
Short Term Borrowings
768.60
1,081.00
3,314.10
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
Short Term Provisions
766.80
522.20
407.40
418.30
272.30
189.40
152.20
68.90
81.30
382.50
Total Liabilities
27,634.40
24,490.00
26,687.00
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
Net Block
12,368.50
11,520.90
12,188.50
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
Gross Block
19,919.80
18,343.80
17,650.90
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
Accumulated Depreciation
7,551.30
6,822.90
5,462.40
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
Non Current Assets
16,135.20
14,477.60
14,438.20
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
Capital Work in Progress
2,423.30
1,200.70
725.90
783.20
741.50
837.20
1,527.20
1,543.30
950.80
797.90
Non Current Investment
968.00
927.30
934.80
631.20
552.20
443.60
470.90
385.70
217.10
33.20
Long Term Loans & Adv.
344.50
358.70
369.30
323.30
332.00
410.40
300.00
384.70
661.20
637.10
Other Non Current Assets
30.90
470.00
219.70
223.80
262.10
159.80
130.30
234.10
174.70
0.00
Current Assets
11,419.80
10,008.20
12,095.20
8,716.00
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
Current Investments
252.50
619.30
2,353.20
198.90
212.80
229.90
274.80
49.10
199.10
121.20
Inventories
3,441.90
3,413.30
3,719.40
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
Sundry Debtors
5,220.20
4,416.80
3,340.30
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
Cash & Bank
1,105.10
573.10
1,106.90
888.30
964.90
548.90
1,314.90
1,543.50
638.70
669.90
Other Current Assets
1,400.10
274.00
229.90
523.90
1,085.50
1,080.50
1,048.40
348.50
358.90
311.50
Short Term Loans & Adv.
735.90
711.70
1,345.50
741.40
643.90
584.50
527.70
268.50
234.80
240.80
Net Current Assets
6,080.10
4,481.50
4,268.40
854.70
446.00
1,155.60
2,146.70
716.50
819.40
941.60
Total Assets
27,555.00
24,485.80
26,533.40
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
3,227.90
2,688.80
2,104.50
3,293.90
2,931.50
1,281.90
919.30
1,311.70
1,893.50
993.60
PBT
4,838.10
2,582.70
5,232.30
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
Adjustment
546.70
933.90
-2,117.20
1,163.00
1,474.40
539.10
624.30
333.70
249.80
344.50
Changes in Working Capital
-871.10
-235.80
-336.00
191.10
263.80
-971.70
-1,383.90
-411.20
271.70
-377.00
Cash after chg. in Working capital
4,513.70
3,280.80
2,779.10
3,638.90
3,233.60
1,949.50
1,552.40
1,534.40
2,620.20
1,413.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,285.80
-592.00
-674.60
-345.00
-302.50
-675.40
-602.30
-237.60
-646.00
-386.90
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.40
7.80
-30.80
14.90
-80.70
-32.50
Cash From Investing Activity
-1,475.20
1,535.00
-1,000.30
-724.60
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
-464.70
Net Fixed Assets
-572.20
-669.30
-490.20
-462.80
-289.60
-1,652.30
-600.20
-557.40
-531.50
-271.50
Net Investments
-2,403.70
238.70
1,352.60
-66.50
-2,208.90
-577.10
305.60
-1,606.20
-108.40
-651.40
Others
1,500.70
1,965.60
-1,862.70
-195.30
1,486.20
-2,009.30
-679.10
-708.30
-223.60
458.20
Cash from Financing Activity
-1,810.40
-4,400.40
-868.30
-2,547.70
-1,528.20
1,884.60
51.50
2,315.80
-934.80
-351.10
Net Cash Inflow / Outflow
-57.70
-176.60
235.90
21.60
391.00
-1,072.20
-2.90
755.60
95.20
177.80
Opening Cash & Equivalents
487.80
657.80
888.30
1,177.70
778.80
1,589.70
1,592.60
837.00
737.90
612.60
Closing Cash & Equivalent
413.00
487.80
1,106.90
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00
790.40

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
197.11
173.08
166.01
126.88
101.33
101.43
85.40
67.97
55.66
41.52
ROA
14.70%
7.82%
9.40%
9.66%
5.18%
9.34%
11.11%
12.18%
20.14%
13.93%
ROE
20.52%
11.60%
15.51%
18.88%
11.32%
19.36%
22.26%
23.43%
38.62%
30.85%
ROCE
24.90%
13.64%
15.30%
14.23%
10.02%
15.89%
18.41%
16.50%
28.60%
23.21%
Fixed Asset Turnover
1.98
1.88
1.69
1.69
0.88
1.05
1.38
1.38
1.76
1.80
Receivable days
46.37
41.75
39.94
42.92
97.49
99.21
83.37
76.72
63.29
56.38
Inventory Days
32.98
38.39
42.95
38.08
70.13
70.33
63.69
59.88
54.52
60.13
Payable days
147.51
145.80
166.64
189.45
64.85
68.81
68.11
74.18
65.30
55.05
Cash Conversion Cycle
-68.16
-65.67
-83.76
-108.45
102.77
100.73
78.94
62.42
52.51
61.46
Total Debt/Equity
0.04
0.07
0.25
0.35
0.77
0.76
0.62
0.75
0.43
0.62
Interest Cover
60.22
20.94
23.35
16.11
5.38
13.17
21.87
26.55
40.75
22.29

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Zydus Lifesciences gets USFDA’s approval for Glatiramer Acetate Injection
    9th May 2025, 09:17 AM

    Zydus’ generic Glatiramer Acetate Injection, developed in collaboration with Chemi S.p.A., will be manufactured entirely in Europe

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Niacin Extended-Release Tablets
    30th Apr 2025, 12:23 PM

    Niacin-Extended-Release tablets will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad

    Read More
  • USFDA concludes surveillance inspection at Zydus group’s API unit in Gujarat
    28th Apr 2025, 10:08 AM

    The inspection concluded with 6 observations and none of them were related to Data Integrity

    Read More
  • Zydus Lifesciences’ arm enters into strategic partnership with Braile Biomedica Industria
    19th Apr 2025, 14:06 PM

    This agreement marks a significant step in Zydus MedTech’s strategic expansion into the fast-growing interventional cardiology segment

    Read More
  • Zydus Lifesciences’ venture capital arm invests in Feldan Therapeutics
    17th Apr 2025, 09:48 AM

    Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities

    Read More
  • Zydus Lifesciences’ US division recalls 3,144 bottles of chlorproMAZINE Hydrochloride Tablets
    14th Apr 2025, 14:16 PM

    The drug firm is recalling the affected lot due to CGMP deviations

    Read More
  • Zydus Lifesciences’ arm incorporates wholly owned subsidiary in France
    12th Apr 2025, 12:36 PM

    Zydus MedTech (France) SAS will be acquiring the equity shares of the Amplitude Surgical SA, France

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Jaythari (Deflazacort) Tablets
    12th Apr 2025, 10:39 AM

    Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy in patients 5 years of age and older

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Apalutamide Tablets
    19th Mar 2025, 09:26 AM

    Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Eluxadoline tablets
    17th Mar 2025, 10:30 AM

    Eluxadoline tablets will be produced at Zydus Lifesciences (SEZ), Ahmedabad

    Read More
  • USFDA concludes inspection at Zydus group’s API Unit 1 in Gujarat
    15th Mar 2025, 12:37 PM

    The inspection concluded with NIL observations

    Read More
  • Zydus Lifesciences’ venture capital arm invests in Illexcor Therapeutics
    13th Mar 2025, 09:27 AM

    Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Methenamine Hippurate Tablets
    12th Mar 2025, 16:30 PM

    Methenamine Hippurate tablets will be produced at Zydus Lifesciences (SEZ), Ahmedabad

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Ketoconazole Shampoo
    10th Mar 2025, 12:20 PM

    Ketoconazole shampoo will be produced at the Group’s topical manufacturing site at Changodar, Ahmedabad

    Read More
  • Zydus Lifesciences gets final nod to manufacture Dasatinib Tablets
    6th Mar 2025, 10:29 AM

    Dasatinib tablets had annual sales of $1807.7 million in the United States

    Read More
  • Zydus Lifesciences launches ANVIMO for transplant patients
    5th Mar 2025, 12:12 PM

    With the launch of ANVIMO, the company has significantly reduced the cost by 91% of the innovator price

    Read More
  • Zydus Lifesciences to develop world’s first combination vaccine against shigellosis and typhoid
    4th Mar 2025, 14:11 PM

    The project is expected to get underway in March 2025, and is being supported by the Gates Foundation

    Read More
  • Zydus Lifesciences to launch vaccine for new strain of influenza virus
    27th Feb 2025, 10:30 AM

    Zydus's Quadrivalent Inactivated Influenza vaccine VaxiFlu-4 will offer seasonal protection against four new virus strains

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Ibuprofen and Famotidine Tablets
    22nd Feb 2025, 14:58 PM

    Ibuprofen and Famotidine tablets had annual sales of $3.6 million in the United States

    Read More
  • Zydus Lifesciences’ arm inks pact with Zhuhai Beihai Biotech Co
    14th Feb 2025, 18:01 PM

    The partnership will provide impetus to company’s strategic focus on high unmet need therapy area

    Read More
  • Zydus Lifesciences signs pact with Synthon BV
    13th Feb 2025, 12:59 PM

    Zydus will be responsible for the NDA submission and commercialisation of the product in the US

    Read More
  • Zydus Lifesciences reports 30% rise in Q3 consolidated net profit
    5th Feb 2025, 17:18 PM

    Total consolidated income of the company increased by 17.25% at Rs 5326.6 crore for Q3FY25

    Read More
  • Zydus Lifesciences - Quarterly Results
    5th Feb 2025, 12:24 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.